A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients

NCT02034747 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplant

Interventions

DRUG: Advagraf
DRUG: Corticosteroid

Sponsor

Astellas Pharma Korea, Inc.